John Sourbeer
Stock Analyst at UBS
(0.82)
# 4,155
Out of 5,182 analysts
44
Total ratings
47.62%
Success rate
-16.98%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $11 → $13 | $10.10 | +23.76% | 7 | Nov 5, 2025 | |
| ILMN Illumina | Maintains: Neutral | $110 → $120 | $126.92 | -5.45% | 6 | Oct 31, 2025 | |
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $292.13 | +21.52% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $46 → $48 | $34.02 | +39.98% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $102.49 | +134.17% | 2 | Jul 25, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $16.21 | +44.97% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $12.02 | +274.38% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.58 | +26.58% | 3 | Nov 11, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $409.65 | +17.17% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $36.26 | +181.30% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $21.37 | +133.97% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $93.86 | +36.37% | 2 | Jul 27, 2022 |
Cryoport
Nov 5, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $10.10
Upside: +23.76%
Illumina
Oct 31, 2025
Maintains: Neutral
Price Target: $110 → $120
Current: $126.92
Upside: -5.45%
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $292.13
Upside: +21.52%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $46 → $48
Current: $34.02
Upside: +39.98%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $102.49
Upside: +134.17%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $16.21
Upside: +44.97%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $12.02
Upside: +274.38%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.58
Upside: +26.58%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $409.65
Upside: +17.17%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $36.26
Upside: +181.30%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $21.37
Upside: +133.97%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $93.86
Upside: +36.37%